WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
TERN
TERNS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$299.98M$4.64-2.32%-$89.09M-3.65x0.05
ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.69B$16.31-1.69%-$45.48M-44.08x0.74
PMCB
PHARMACYTE BIOTECH INC
NASDAQ
Biotechnology
$17.95M$2.12-3.64%-$1.14M-1.77x0.72
TBPH
THERAVANCE BIOPHARMA INC
NASDAQ
Biotechnology
$440.23M$9.14-0.33%-$40.77M-9.14x0.79
SNSE
SENSEI BIOTHERAPEUTICS INC
NASDAQ
Biotechnology
$25.07M$1.000.81%-$31.25M-0.82x0.15
RLAY
RELAY THERAPEUTICS INC
NASDAQ
Biotechnology
$807.41M$6.16-3.07%-$336.70M-2.21x0.12
DMAC
DIAMEDICA THERAPEUTICS INC
NASDAQ
Biotechnology
$96.03M$2.533.27%-$19.16M-4.22x0.06
MNKD
MANNKIND CORP
NASDAQ
Biotechnology
$1.13B$4.18-0.24%$20.62M-104.50x-2.93
OCUL
OCULAR THERAPEUTIX INC
NASDAQ
Biotechnology
$624.24M$4.20-9.58%-$66.42M-4.16x1.77
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
NASDAQ
Biotechnology
$378.69M$2.610.38%-$182.30M-1.67x1.14
PHAR
PHARMING GROUP NV
NASDAQ
Biotechnology
$701.27M$10.456.31%$4.25M-60.06x1.12
URGN
UROGEN PHARMA LTD
NASDAQ
Biotechnology
$471.57M$13.82-2.74%-$81.90M-3.89x-3.73
OCGN
OCUGEN INC
NASDAQ
Biotechnology
$303.64M$1.180.00%-$61.84M-4.54x0.59
PULM
PULMATRIX INC
NASDAQ
Biotechnology
$7.60M$2.082.97%-$12.65M-0.54x0.89
FOLD
AMICUS THERAPEUTICS INC
NASDAQ
Biotechnology
$3.00B$10.17-3.51%-$92.08M-19.94x3.86
RXRX
RECURSION PHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.84B$7.84-1.26%-$299.66M-4.96x0.41
CLLS
CELLECTIS SA
NASDAQ
Biotechnology
$138.40M$2.49-0.40%-$27.35M-1.51x1.76
IMRN
IMMURON LTD
NASDAQ
Biotechnology
$13.84M$2.43-2.41%N/A-5.56x0.13
HOOK
HOOKIPA PHARMA INC
NASDAQ
Biotechnology
$79.75M$0.81-5.18%-$77.34M-0.94x0.80
CANF
CAN-FITE BIOPHARMA LTD
NYSEMKT
Biotechnology
$7.83M$1.92-1.03%-$7.53M-0.64x0.60
SILO
SILO PHARMA INC
NASDAQ
Biotechnology
$5.35M$1.880.00%-$3.70M-1.57x0.25
BLRX
BIOLINERX LTD
NASDAQ
Biotechnology
$41.86M$0.58-6.20%-$57.06M-9.58x3.83
IPHA
INNATE PHARMA SA
NASDAQ
Biotechnology
$193.09M$2.40-2.44%-$700.00k-24.49x2.55
AADI
AADI BIOSCIENCE INC
NASDAQ
Biotechnology
$41.25M$1.68-5.62%-$64.90M-0.69x0.26
CRVO
CERVOMED INC
NASDAQ
Biotechnology
$154.20M$24.991.59%-$2.17M-30.48x0.35
PSTX
POSEIDA THERAPEUTICS INC
NASDAQ
Biotechnology
$197.80M$2.05-0.97%-$109.04M-1.50x1.64
RGNX
REGENXBIO INC
NASDAQ
Biotechnology
$713.51M$16.060.12%-$239.46M-2.67x0.84
TCRT
ALAUNOS THERAPEUTICS INC
NASDAQ
Biotechnology
$18.57M$1.16-1.69%-$30.62M-0.53x0.31
MRNA
MODERNA INC
NASDAQ
Biotechnology
$40.57B$106.18-2.45%-$3.32B-8.61x0.33
RPTX
REPARE THERAPEUTICS INC
NASDAQ
Biotechnology
$132.87M$3.15-4.55%-$99.03M-1.41x0.20
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
NASDAQ
Biotechnology
$1.91B$7.58-1.17%$731.76M-8.42x1.67
STOK
STOKE THERAPEUTICS INC
NASDAQ
Biotechnology
$541.29M$11.690.26%-$109.88M-4.91x0.43
BRTX
BIORESTORATIVE THERAPIES INC
NASDAQ
Biotechnology
$8.33M$1.23-3.15%-$14.16M-0.36x0.09
LEXX
LEXARIA BIOSCIENCE CORP
NASDAQ
Biotechnology
$28.22M$2.19-0.45%-$5.24M-3.22x0.03
PCSA
PROCESSA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$6.94M$2.4350.00%-$11.04M-0.29x0.16
KRON
KRONOS BIO INC
NASDAQ
Biotechnology
$58.89M$0.982.08%-$107.76M-0.50x0.34
PASG
PASSAGE BIO INC
NASDAQ
Biotechnology
$67.83M$1.22-1.61%-$98.34M-0.66x0.35
KURA
KURA ONCOLOGY INC
NASDAQ
Biotechnology
$1.45B$19.001.33%-$150.23M-9.13x0.13
KTTA
PASITHEA THERAPEUTICS CORP
NASDAQ
Biotechnology
$7.55M$7.244.17%-$15.31M-0.56x0.12
OMGA
OMEGA THERAPEUTICS INC
NASDAQ
Biotechnology
$129.61M$2.350.86%-$90.66M-1.31x2.52
ORIC
ORIC PHARMACEUTICALS INC
NASDAQ
Biotechnology
$516.77M$7.67-5.07%-$99.67M-3.91x0.13
NXTC
NEXTCURE INC
NASDAQ
Biotechnology
$35.99M$1.29-10.42%-$58.47M-0.57x0.12
SNDX
SYNDAX PHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.75B$20.57-1.06%-$208.40M-6.90x0.11
IPSC
CENTURY THERAPEUTICS INC
NASDAQ
Biotechnology
$204.18M$3.156.42%-$122.40M-1.37x0.95
IMRX
IMMUNEERING CORP
NASDAQ
Biotechnology
$41.88M$1.43-4.67%-$52.71M-0.76x0.13
ACET
ADICET BIO INC
NASDAQ
Biotechnology
$148.70M$1.81-3.47%-$133.69M-0.55x0.22
PMVP
PMV PHARMACEUTICALS INC
NASDAQ
Biotechnology
$87.97M$1.711.18%-$68.07M-1.19x0.12
VRCA
VERRICA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$282.08M$6.65-2.06%-$62.20M-4.49x3.13
DYAI
DYADIC INTERNATIONAL INC
NASDAQ
Biotechnology
$43.17M$1.49-0.67%-$6.80M-6.21x0.40
MORF
MORPHIC HOLDING INC
NASDAQ
Biotechnology
$1.40B$27.981.05%-$159.71M-7.99x0.03
EQ
EQUILLIUM INC
NASDAQ
Biotechnology
$63.81M$1.811.12%-$12.14M-4.76x1.24
LVTX
LAVA THERAPEUTICS NV
NASDAQ
Biotechnology
$69.40M$2.64-3.65%-$47.16M-1.55x0.99
AVIR
ATEA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$310.57M$3.69-0.27%-$134.52M-2.26x0.07
CGEM
CULLINAN THERAPEUTICS INC
NASDAQ
Biotechnology
$829.01M$19.251.91%-$166.97M-5.22x0.07
ACST
ACASTI PHARMA INC
NASDAQ
Biotechnology
$27.53M$2.931.00%-$48.89M-0.58x0.18
GLTO
GALECTO INC
NASDAQ
Biotechnology
$18.14M$0.67-0.30%-$37.52M-0.46x0.18
CLSD
CLEARSIDE BIOMEDICAL INC
NASDAQ
Biotechnology
$94.15M$1.26-5.97%-$32.42M-2.38x-3.14
LGND
LIGAND PHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.25B$70.37-0.89%N/AN/A0.12
CBUS
CIBUS INC
NASDAQ
Biotechnology
$375.01M$15.541.83%-$244.57M-0.60x0.70
SABS
SAB BIOTHERAPEUTICS INC
NASDAQ
Biotechnology
$36.99M$4.01-8.86%-$38.13M-0.52x0.47
CGON
CG ONCOLOGY INC
NASDAQ
Biotechnology
$2.41B$36.200.42%-$55.48M-2.31x-0.12
CRMD
CORMEDIX INC
NASDAQ
Biotechnology
$285.35M$5.19-2.63%-$46.23M-5.70x0.17
XENE
XENON PHARMACEUTICALS INC
NASDAQ
Biotechnology
$3.02B$40.101.52%-$179.14M-14.69x0.04
VRAX
VIRAX BIOLABS GROUP LTD
NASDAQ
Biotechnology
$1.27M$0.705.42%N/A-0.24x0.15
ATHA
ATHIRA PHARMA INC
NASDAQ
Biotechnology
$73.59M$1.92-4.48%-$116.49M-0.62x0.23
ARTL
ARTELO BIOSCIENCES INC
NASDAQ
Biotechnology
$4.33M$1.34-0.15%-$9.25M-0.43x0.11
BNTC
BENITEC BIOPHARMA INC
NASDAQ
Biotechnology
$17.99M$6.943.27%-$21.44M-64.26x0.38
BDTX
BLACK DIAMOND THERAPEUTICS INC
NASDAQ
Biotechnology
$264.28M$5.110.99%-$82.01M-2.72x0.36
EXAI
EXSCIENTIA PLC
NASDAQ
Biotechnology
$501.55M$3.99-3.39%-$192.47M-2.64x0.44
DOMH
DOMINARI HOLDINGS INC
NASDAQ
Biotechnology
$16.02M$2.70-2.17%-$22.44M-0.62x0.09
PRLD
PRELUDE THERAPEUTICS INC
NASDAQ
Biotechnology
$221.88M$4.044.39%-$118.73M-2.00x0.17
NRIX
NURIX THERAPEUTICS INC
NASDAQ
Biotechnology
$607.50M$12.36-10.11%-$130.28M-4.65x0.85
VCEL
VERICEL CORP
NASDAQ
Biotechnology
$2.19B$45.45-1.43%$8.93M-649.29x0.57
PCVX
VAXCYTE INC
NASDAQ
Biotechnology
$6.51B$60.06-0.40%-$392.10M-14.51x0.14
NKTX
NKARTA INC
NASDAQ
Biotechnology
$337.02M$6.82-4.88%-$109.41M-2.84x0.39
XBIT
XBIOTECH INC
NASDAQ
Biotechnology
$250.00M$8.211.73%-$22.57M-10.14x0.04
ZNTL
ZENTALIS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$779.50M$10.99-6.67%-$291.40M-2.46x0.26
STRO
SUTRO BIOPHARMA INC
NASDAQ
Biotechnology
$213.55M$3.42-1.44%-$66.98M-1.92x2.15
CNTA
CENTESSA PHARMACEUTICALS PLC
NASDAQ
Biotechnology
$895.73M$8.93-5.60%-$165.43M-5.69x0.53
ANNX
ANNEXON INC
NASDAQ
Biotechnology
$413.22M$4.593.15%-$130.97M-2.59x0.19
LTRN
LANTERN PHARMA INC
NASDAQ
Biotechnology
$58.65M$5.461.49%-$15.79M-3.71x0.07
ADMA
ADMA BIOLOGICS INC
NASDAQ
Biotechnology
$1.47B$6.44-0.31%$5.12M-49.54x1.44
VXRT
VAXART INC
NASDAQ
Biotechnology
$114.40M$0.66-7.32%-$73.58M-1.15x0.59
LPTX
LEAP THERAPEUTICS INC
NASDAQ
Biotechnology
$81.15M$3.17-3.65%-$81.40M-0.80x0.21
ABEO
ABEONA THERAPEUTICS INC
NASDAQ
Biotechnology
$87.26M$3.190.63%-$50.57M-1.26x3.32
QNCX
QUINCE THERAPEUTICS INC
NASDAQ
Biotechnology
$44.51M$1.03-2.83%-$31.26M-1.23x0.97
GDTC
CYTOMED THERAPEUTICS LTD
NASDAQ
Biotechnology
$25.39M$2.202.33%-$2.72M-7.67x0.10
NUVB
NUVATION BIO INC
NYSE
Biotechnology
$573.90M$2.62-1.50%-$75.65M-7.49x0.03
GPCR
STRUCTURE THERAPEUTICS INC
NASDAQ
Biotechnology
$1.81B$38.987.00%-$88.46M-16.04x0.06
ALDX
ALDEYRA THERAPEUTICS INC
NASDAQ
Biotechnology
$232.05M$3.940.00%-$35.21M-6.16x0.24
CDTX
CIDARA THERAPEUTICS INC
NASDAQ
Biotechnology
$59.30M$13.005.78%-$21.21M-2.50x-9.16
PTIX
PROTAGENIC THERAPEUTICS INC
NASDAQ
Biotechnology
$6.96M$1.57-4.21%-$4.86M-1.36x0.18
TYRA
TYRA BIOSCIENCES INC
NASDAQ
Biotechnology
$793.59M$15.11-5.56%-$68.78M-9.33x0.11
EPIX
ESSA PHARMA INC
NASDAQ
Biotechnology
$270.74M$6.12-2.08%-$25.69M-10.37x0.03
ENTX
ENTERA BIO LTD
NASDAQ
Biotechnology
$70.96M$2.00-3.38%-$8.80M-6.45x0.13
ERAS
ERASCA INC
NASDAQ
Biotechnology
$284.81M$1.880.00%-$121.31M-2.27x0.25
VRNA
VERONA PHARMA PLC
NASDAQ
Biotechnology
$1.24B$15.310.46%-$51.16M-21.26x0.24
MACK
MERRIMACK PHARMACEUTICALS INC
NASDAQ
Biotechnology
$213.82M$14.730.14%-$1.17M-184.13x0.02
CELC
CELCUITY INC
NASDAQ
Biotechnology
$480.25M$15.77-6.91%-$58.31M-5.86x0.37
CNTB
CONNECT BIOPHARMA HOLDINGS LTD
NASDAQ
Biotechnology
$74.94M$1.36-0.73%-$59.36M-1.26x0.25

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -30.41% over the past year, underperforming other biotech stocks by -7 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 45.94% from Incyte's current stock price of $51.18.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -8.91% over the past year, overperforming other biotech stocks by 15 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 29.05% from Harmony Biosciences Holdings's current stock price of $28.93.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -1.33% over the past year, overperforming other biotech stocks by 22 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 176.28% from Voyager Therapeutics's current stock price of $7.42.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 14.87%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 56.45%, which is 42 percentage points higher than the biotech industry average of 14.87%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.09%, which is -14 percentage points lower than the biotech industry average of 14.87%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.43% in the last day, and down -0.98% over the last week. Acrivon Therapeutics was the among the top losers in the biotechnology industry, dropping -10.84% yesterday.

Acrivon Therapeutics shares are trading higher after the company reported initial clinical data for ACR-368 and pipeline program progress today at a corporate R&D event.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -21.04% in the past year. It has overperformed other stocks in the biotech industry by 3 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -1.33% in the past year. It has overperformed other stocks in the biotech industry by 22 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -30.41% in the past year. It has underperformed other stocks in the biotech industry by -7 percentage points.

Are biotech stocks a good buy now?

49.03% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 94.43% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.41x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.